Preview: Autoimmune & inflammatory diseases

Autoimmune and inflammatory diseases remain one of Europe’s most active areas of biotech innovation. From inflammatory bowel disease, psoriasis and atopic dermatitis to lupus, vasculitis, multiple sclerosis and rare immune-mediated disorders, European companies are helping reshape how chronic inflammation is understood and treated. The field is moving beyond broad immunosuppression towards more precise approaches: targeted antibodies, cytokine modulators, complement inhibitors, RNA medicines, microbiome-linked therapies, new biomarkers and AI-supported innovation. In its Autumn 2026 issue, European Biotechnology Magazine will spotlight the companies, technologies and clinical programmes driving this shift across Europe.

Examples of topics

Targeted immunology, cytokine biology, T-cell modulation, B-cell therapies, complement biology, inflammasome inhibition, inflammatory bowel disease, dermatology, rheumatology, neuroinflammation, rare autoimmune disorders, biomarkers, companion diagnostics, microbiome approaches, bispecific antibodies, AI-supported drug discovery, clinical trial design, regulatory strategy, etc.

Interested in advertising with us? We’re happy to advise you!